PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Summit Therapeutics Inc. (SMMT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US86627T1088

CUSIP

86627T108

Sector

Healthcare

IPO Date

Mar 5, 2015

Highlights

Market Cap

$13.78B

EPS (TTM)

-$0.23

Total Revenue (TTM)

-$235.00K

Gross Profit (TTM)

-$907.00K

EBITDA (TTM)

-$184.77M

Year Range

$2.10 - $33.89

Target Price

$33.01

Short %

14.17%

Short Ratio

8.65

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
SMMT vs. SPY SMMT vs. TIL SMMT vs. xbi SMMT vs. MSOS SMMT vs. PHM SMMT vs. VKTX SMMT vs. VOO SMMT vs. QQQ SMMT vs. RSG SMMT vs. ARQT
Popular comparisons:
SMMT vs. SPY SMMT vs. TIL SMMT vs. xbi SMMT vs. MSOS SMMT vs. PHM SMMT vs. VKTX SMMT vs. VOO SMMT vs. QQQ SMMT vs. RSG SMMT vs. ARQT

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Summit Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%100.00%200.00%300.00%JulyAugustSeptemberOctoberNovemberDecember
117.67%
7.29%
SMMT (Summit Therapeutics Inc.)
Benchmark (^GSPC)

Returns By Period

Summit Therapeutics Inc. had a return of 550.57% year-to-date (YTD) and 533.58% in the last 12 months.


SMMT

YTD

550.57%

1M

-10.54%

6M

113.85%

1Y

533.58%

5Y*

63.72%

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of SMMT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202450.19%15.82%-8.81%-5.07%120.99%-10.19%38.46%20.19%68.72%-15.11%-0.70%550.57%
2023-16.47%-49.30%-2.78%-24.57%23.48%53.99%-16.33%-22.86%15.43%3.74%4.64%28.57%-38.59%
2022-18.22%24.55%-10.58%-35.10%-16.35%-24.81%1.00%18.81%-0.83%-8.40%-26.61%431.25%57.99%
202148.09%-2.73%-13.29%8.52%22.76%-4.60%-1.74%8.73%-37.14%2.99%-1.55%-47.05%-42.77%
2020-4.38%-9.80%71.74%58.23%7.73%-26.49%21.89%-4.70%-0.29%-4.94%37.61%4.44%193.75%
201915.65%72.93%-20.43%-3.55%-13.88%-16.78%4.35%1.29%33.88%-7.82%-9.09%6.67%39.13%
201823.92%-14.71%10.16%1.01%2.46%-81.65%-6.12%2.17%-5.53%-23.42%-23.53%-11.54%-89.62%
201722.31%16.62%8.72%-17.14%1.09%2.43%22.74%-7.94%-2.49%-18.09%14.49%-5.86%29.44%
2016-21.74%-25.00%1.04%46.33%-13.83%-5.93%-13.47%-5.14%36.51%29.85%-10.88%-18.40%-25.57%
201521.59%-15.74%-0.57%1.75%22.61%-8.11%-12.52%-2.98%3.56%9.94%12.86%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 97, SMMT is among the top 3% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of SMMT is 9797
Overall Rank
The Sharpe Ratio Rank of SMMT is 9393
Sharpe Ratio Rank
The Sortino Ratio Rank of SMMT is 9999
Sortino Ratio Rank
The Omega Ratio Rank of SMMT is 9898
Omega Ratio Rank
The Calmar Ratio Rank of SMMT is 9999
Calmar Ratio Rank
The Martin Ratio Rank of SMMT is 9898
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for SMMT, currently valued at 1.98, compared to the broader market-4.00-2.000.002.001.981.90
The chart of Sortino ratio for SMMT, currently valued at 5.32, compared to the broader market-4.00-2.000.002.004.005.322.54
The chart of Omega ratio for SMMT, currently valued at 1.70, compared to the broader market0.501.001.502.001.701.35
The chart of Calmar ratio for SMMT, currently valued at 6.93, compared to the broader market0.002.004.006.006.932.81
The chart of Martin ratio for SMMT, currently valued at 23.80, compared to the broader market0.0010.0020.0023.8012.39
SMMT
^GSPC

The current Summit Therapeutics Inc. Sharpe ratio is 1.98. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Summit Therapeutics Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.002.003.004.005.00JulyAugustSeptemberOctoberNovemberDecember
1.98
1.90
SMMT (Summit Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Summit Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-46.82%
-3.58%
SMMT (Summit Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Summit Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Summit Therapeutics Inc. was 95.75%, occurring on Dec 1, 2022. Recovery took 443 trading sessions.

The current Summit Therapeutics Inc. drawdown is 46.82%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.75%Sep 12, 20171316Dec 1, 2022443Sep 9, 20241759
-59.8%Apr 7, 2015366Sep 15, 201613Oct 4, 2016379
-46.82%Sep 16, 202467Dec 18, 2024
-43.41%Oct 6, 201659Dec 29, 2016151Aug 7, 2017210
-16.79%Aug 8, 20175Aug 14, 201717Sep 7, 201722

Volatility

Volatility Chart

The current Summit Therapeutics Inc. volatility is 17.80%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%JulyAugustSeptemberOctoberNovemberDecember
17.80%
3.64%
SMMT (Summit Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Summit Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Summit Therapeutics Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab